Who are PROVARIX's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): recombinant adjuvanted zoster vaccine, Zoster Vaccine Recombinant, Adjuvanted, recombinant subunit Herpes zoster vaccine, Zoster Vaccine Recombinant, RZV, RSVpreF 120 µg.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/provarix.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

PROVARIX — Competitive Intelligence Brief

PROVARIX (PROVARIX) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant subunit vaccine. Area: Immunology / Infectious Disease.

phase 3 Recombinant subunit vaccine Varicella-zoster virus glycoprotein E (gE) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

PROVARIX (PROVARIX) — Sinovac (Dalian) Vaccine Technology Co., Ltd.. PROVARIX is a recombinant varicella-zoster virus (VZV) vaccine designed to prevent herpes zoster (shingles) and post-herpetic neuralgia in immunocompetent and immunocompromised populations.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
PROVARIX TARGET	PROVARIX	Sinovac (Dalian) Vaccine Technology Co., Ltd.	phase 3	Recombinant subunit vaccine	Varicella-zoster virus glycoprotein E (gE)
recombinant adjuvanted zoster vaccine	recombinant adjuvanted zoster vaccine	Wuerzburg University Hospital	marketed	Recombinant subunit vaccine with adjuvant	Varicella-zoster virus glycoprotein E (gE)
Zoster Vaccine Recombinant, Adjuvanted	Zoster Vaccine Recombinant, Adjuvanted	Wuhan BravoVax Co., Ltd.	marketed	Recombinant subunit vaccine with adjuvant	Varicella-zoster virus glycoprotein E (gE)
recombinant subunit Herpes zoster vaccine	recombinant subunit Herpes zoster vaccine	University Health Network, Toronto	marketed	Recombinant subunit vaccine	Varicella-zoster virus glycoprotein E (gE)
Zoster Vaccine Recombinant	Zoster Vaccine Recombinant	University of Colorado, Denver	marketed	Recombinant subunit vaccine	Varicella-zoster virus glycoprotein E (gE)
RZV	RZV	GlaxoSmithKline	marketed	Recombinant subunit vaccine	Varicella-zoster virus glycoprotein E (gE)
RSVpreF 120 µg	rsvpref-120-g	Pfizer	marketed	Recombinant subunit vaccine	Prefusion form of the RSV F protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant subunit vaccine class)

GlaxoSmithKline · 3 drugs in this class
Pfizer · 1 drug in this class
Sinovac (Dalian) Vaccine Technology Co., Ltd. · 1 drug in this class
University Health Network, Toronto · 1 drug in this class
University of Colorado, Denver · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PROVARIX — Competitive Intelligence Brief. https://druglandscape.com/ci/provarix. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab